Abstract: Provided are compositions and methods for treating bacterial infections. It is demonstrated herein that bacteria cell wall materials stimulate germination of spores of Gram-positive bacteria, and that such activity requires Ser/Thr kinase PrkC. By modulating one or both, spores (which can be antibiotic resistant) can be stimulated or inhibited from germination, which can be exploited in various methods of therapeutic treatment. Also provided is a method of modulating germination of a spore of a Gram-positive bacterium. Also provided is a method of decontaminating an environment.
Type:
Application
Filed:
March 26, 2010
Publication date:
April 14, 2011
Applicant:
The Trustees of Columbia University in the City of New York
Abstract: The present invention is a method for preventing or treating an immune-relevant disease by modulating commensal microbiota populations via antibiotics, exogenous microbiota and/or probiotics.
Abstract: Biomass (e.g., plant biomass, animal biomass, microbial, and municipal waste biomass) is processed to produce useful products, such as food products and amino acids.
Abstract: Biomass (e.g., plant biomass, animal biomass, microbial, and municipal waste biomass) is processed to produce useful products, such as food products and amino acids.
Abstract: The present invention is directed to methods of inhibition, delay of formation, treatment, prophylaxis and/or prevention of infections caused by bacteria that exhibit tolerance to antimicrobial agents, including slow growing, stationary-phase and biofilm forming bacteria, through the use of glycopeptide antibiotics, such as oritavancin.
Type:
Application
Filed:
April 2, 2009
Publication date:
February 24, 2011
Applicant:
TARGANTA THERAPEUTICS CORP.
Inventors:
Eve Neesham-Grenon, Gregory Moeck, Adam Belley, Thomas R. Parr, JR., Adel Rafai Far
Abstract: The present invention is concerned with novel immunostimulant microparticle compositions and their use as anti-infective agents in the treatment of bacterial and viral infections.
Type:
Application
Filed:
April 1, 2009
Publication date:
February 10, 2011
Applicant:
INNATE THERAPEUTICS LIMITED
Inventors:
Frank B. Gelder, Gillian Alison Webster
Abstract: A device that includes a scaffold composition and a bioactive composition with the bioactive composition being incorporated therein or thereon, or diffusing from the scaffold composition such that the scaffold composition and/or a bioactive composition captures and eliminates undesirable cells from the body a mammalian subject. The devices mediate active recruitment, sequestration, and removal or elimination of undesirable cells from their host.
Type:
Application
Filed:
June 11, 2008
Publication date:
January 27, 2011
Inventors:
David James Mooney, Omar abdel-Rahman Ali
Abstract: Semi-synthetic glycopeptides having antibacterial activity are described, in particular, the semi-synthetic glycopeptides described herein are made by chemical modification of a glycopeptide (Compound A, Compound B, Compound H or Compound C) or monosaccharide made by hydrolyzing the disaccharide moiety of the amino acid-4 of the parent glycopeptide in acidic medium to give the amino acid-4 monosaccharide; conversion of the monosaccharide to the amino-sugar derivative; acylation of the amino substituent on the amino acid-4 amino-substituted sugar moiety on these scaffolds with certain acyl groups; and conversion of the acid moiety on the macrocyclic ring of these scaffolds to certain substituted amides. Key reaction is the treatment of properly protected intermediate compound with isocyanate.
Abstract: Compositions and methods, including novel homogeneous microparticulate suspensions, are described for treating acute wounds, chronic wounds and/or a wound or epithelial tissue surface that contains bacterial biofilm, including unexpected synergy between bismuth-thiol (BT) compounds and certain antibiotics, to provide topical formulations including antiseptic formulations, for management and promotion of wound healing and in particular infected wounds. Previously unpredicted antibacterial properties and anti-biofilm properties of disclosed BT compounds and BT compound-plus-antibiotic combinations are also described, including preferential efficacies of certain such compositions for treating gram-positive bacterial infections, and distinct preferential efficacies of certain such compositions for treating gram-negative bacterial infections.
Abstract: Glycopeptide antibiotics, such as oritavancin, demonstrate significant activity against both a vegetative form of C. difficile and C. difficile spores. Methods for the treatment, prophylaxis and prevention of C. difficile infection and disease in animals, including humans, are described.
Type:
Application
Filed:
September 11, 2008
Publication date:
December 9, 2010
Applicant:
TARGANTA THERAPEUTICS CORP.
Inventors:
Mark Harvey Wilcox, Simon Baines, Dario Lehoux, Thomas R. Parr
Abstract: An aqueous or powder composition includes anti-gram-negative antibiotic or salt thereof being present at an amount ranging from about 100 mg/ml to about 200 mg/ml. Another aqueous or powder composition includes anti-gram-positive antibiotic or salt thereof being present at a concentration ranging from about 0.6 to about 0.9 of the water solubility limit, at 25° C. and 1.0 atmosphere, of the anti-gram-positive antibiotic or salt thereof. Other embodiments include unit doses, kits, and methods.
Abstract: The present invention is related to a novel functional nanoparticle-based antibiotics and preparation method thereof, especially related to an antibiotics-modified nanoparticle. The functional nanoparticle-based antibiotics according to the present invention can be used as the affinity probes and the photothermal agents to effectively inhibit the cell growth of pathogenic bacteria under NIR irradiation.
Abstract: Compositions and methods and are provided for treating disorders associated with compromised vasculostasis. Invention methods and compositions are useful for treating a variety of disorders including for example, stroke, myocardial infarction, cancer, ischemia/reperfusion injury, autoimmune diseases such as rheumatoid arthritis, eye diseases such as retinopathies or macular degeneration or other vitreoretinal diseases, inflammatory diseases, vascular leakage syndrome, edema, transplant rejection, adult/acute respiratory distress syndrome (ARDS), and the like.
Type:
Application
Filed:
December 1, 2009
Publication date:
November 4, 2010
Inventors:
Wolfgang Wrasidlo, John Doukas, Ivor Royston, Glenn Noronha, John D. Hood, Elena Dneprovskaia, Xianchang Gong, Ute Splittgerber, Ningning Zhao
Abstract: The invention concerns pharmaceutical anhydrous formulation for topical use comprising Vancomycin, Vancomycin Hydrochloride, or Teicoplanin, and Dimethylsulfoxide. In a preferred embodiment the formulation further comprises one or more glycols and/or ethers thereof, and optionally one or more fatty acids triglycerides and/or the polyoxyethylene derivative thereof. The use of Dimethylsulfoxide in anhydrous formulation for topical use leads to formulations characterized by high homogeneity and high concentration, if desired, of Vancomycin, Vancomycin Hydrochloride, or Teicoplanin. These Dimethylsulfoxide-containing formulations are also very stable in time.
Abstract: Aminoglycoside-amino acid and -peptide conjugates comprising a triazolyl linker are provided along with efficient methods of their preparation. The aminoglycoside may be an aminoglycoside antibiotic. Conjugates comprising an aminoglycoside antibiotic may exhibit antimicrobial activities against Gram-positive and/or Gram-negative strains and display significantly enhanced activity against multi-drug resistant MRSA and MRSE when compared to their unconjugated aminoglycoside antibiotic counterparts.
Type:
Application
Filed:
May 28, 2008
Publication date:
October 14, 2010
Applicant:
UNIVERSITY OF MANITOBA
Inventors:
Frank Schweizer, George G. Zhanel, Smritilekha Bera
Abstract: The invention relates to compositions comprising a compound based on the general formula (I) R1-Arg-R2—NH—CH(R3)—CH2—NH—R4??(I) The composition may be used to eliminate and/or reduce microorganisms such as bacteria, viruses, fungi and protozoa.
Type:
Application
Filed:
March 8, 2010
Publication date:
September 30, 2010
Applicant:
Neobiotics AB
Inventors:
Anders Grubb, Aftab Jasir, Claes Schalén, Franciszek Kasprzykowski, Regina Kasprzykowska
Abstract: Methods of preventing or reducing tumor angiogenesis in a subject, comprising administering to the subject one or more agents that inhibit expression or activity of GRP78 are provided. Also provided are methods of sensitizing tumor blood vessels to a chemotherapeutic agent comprising administering to the subject one or more agents that inhibit expression or activity of GRP78. Provided is also a method of reducing tumor microvessel density in a subject, comprising selecting a subject with a tumor, wherein the subject is in need of reduction of tumor microvessel density, and administering to the subject one or more agents that inhibit expression or activity of GRP78.
Abstract: The use of phanquinone for the manufacture of a pharmaceutical composition for the prevention or the treatment of Alzheimer's disease is disclosed. Also methods of treatment or prevention of Alzheimer's disease are disclosed.
Type:
Grant
Filed:
October 19, 2000
Date of Patent:
December 30, 2003
Assignee:
P.N. Gerolymatos S.A.
Inventors:
Michel Xilinas, Panayotis Nikolas Gerolymatos